Low-fat diet reduces female pancreatic cancer risk

Investigative research suggests that diet may affect the risk of pancreatic cancer. The study investigated the effect of a low-fat diet on the incidence of pancreatic cancer.

The Women’s Healthy Diet Changes (WHI-DM) trial is a randomized controlled trial that included 48,835 postmenopausal women aged 50 to 79 years between 1993 and 1998. The enrolled women were randomly assigned to the intervention group (19,541 cases) with the goal of reducing their total fat intake and increasing the intake of vegetables, fruits, and grains; or the normal diet control group (29,294 cases). The intervention group was completed in March 2005. Through the application of log-rank test and multifactor Cox risk proportional model follow-up in 2014, the effect of dietary intervention on the incidence of pancreatic cancer was evaluated.

Intentional analysis included 46 200 women, 92 patients in the intervention group and 165 patients in the control group were diagnosed with pancreatic cancer (P = 0.23), multivariate analysis, the intervention group compared with the control group of pancreatic cancer risk ratio HR) is 0.86 (95% CI 0.67 ~ 1.11). For subjects with a baseline body mass index (BMI) of 25 kg / m2 or more, intervention can reduce the risk of pancreatic cancer (HR = 0.71, 95% CI 0.53 ~ 0.96). Intervention did not significantly reduce the risk of morbidity (HR = 1.62, 95% CI 0.97 ~ 2.71; P = 0.01). 

Susan Hau is a distinguished researcher in the field of cancer cell therapy, with a particular focus on T cell-based approaches and cancer vaccines. Her work spans several innovative treatment modalities, including CAR T-cell therapy, TIL (Tumor-Infiltrating Lymphocyte) therapy, and NK (Natural Killer) cell therapy.

Hau's expertise lies in cancer cell biology, where she has made significant contributions to understanding the complex interactions between immune cells and tumors.

Her research aims to enhance the efficacy of immunotherapies by manipulating the tumor microenvironment and exploring novel ways to activate and direct immune responses against cancer cells.

Throughout her career, Hau has collaborated with leading professors and researchers in the field of cancer treatment, both in the United States and China.

These international experiences have broadened her perspective and contributed to her innovative approach to cancer therapy development.

Hau's work is particularly focused on addressing the challenges of treating advanced and metastatic cancers. She has been involved in clinical trials evaluating the safety and efficacy of various immunotherapy approaches, including the promising Gamma Delta T cell therapy.

  • Comments Closed
  • April 20th, 2020

Five classic signs of pancreatic cancer

Previous Post:
nxt-post

Targeted mass spectrometry can identify benign and malignant pancreatic cysts

Next Post:

Scan the code